drugset / Trial / NCT02353247

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

NCT02353247

Completed 88 enrolled Norton Healthcare
NaSingle-groupOpen-labelTreatment

Summary

The overall objective of this study is to confirm that oral progesterone is an effective way to manage bothersome bleeding; thus increasing the rate of continuation of the etonogestrel contraceptive implant in adolescents.

Timeline

Start
2015-08
Primary completion
2017-06-29
Completion
2017-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Norethindrone Unknown 5 mg Oral

Indications

No indication recorded.